Regeneron (REGN) Tops Q3 EPS by 40c; EYLEA Sales Rose 16%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Regeneron Pharma (REGN) PT Cut at Baird on 'Uneventful Earnings'
November 4, 2016 12:40 PM EDTBaird analyst Brian Skorney lowered his price target on Neutral-rated Regeneron Pharma (NASDAQ: REGN) to $379.00 (from $448.00) following "uneventful earnings."
Skorney commented, "Though earnings were relatively uneventful and the company pulled out an EPS beat on lower operating expenses, Eylea growth continues to... More
